Janus Henderson Group PLC Acquires 641,375 Shares of Abbott Laboratories $ABT

Janus Henderson Group PLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 8.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,092,917 shares of the healthcare product maker’s stock after acquiring an additional 641,375 shares during the period. Janus Henderson Group PLC’s holdings in Abbott Laboratories were worth $830,863,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new stake in Abbott Laboratories in the fourth quarter worth $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at $26,000. Finally, Abound Financial LLC purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at $26,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of recent analyst reports. BTIG Research lifted their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Stifel Nicolaus reduced their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Benchmark dropped their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Barclays reduced their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $108.15 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a market cap of $188.38 billion, a price-to-earnings ratio of 35.00, a price-to-earnings-growth ratio of 2.08 and a beta of 0.61. The firm has a 50-day moving average of $92.72 and a two-hundred day moving average of $100.73. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period last year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS reaffirmed a Buy rating on Abbott, supporting the view that the recent pullback has created an attractive entry point. UBS Issues a Buy Rating on Abbott Laboratories
• Positive Sentiment: TD Cowen maintained its Buy rating and set a $115 price target, citing a strengthening nutrition franchise and 2026 growth opportunities. Abbott Laboratories Buy Rating Backed by Growth Drivers
• Positive Sentiment: Recent quarterly results exceeded expectations, with earnings and revenue above consensus and year-over-year revenue growth of 13%. Coverage also highlights record results and raised outlooks during the current earnings season. Companies Reported Record Results and Raised Guidance
• Positive Sentiment: Analysts continue to see long-term expansion in diabetes care, oncology diagnostics and heart-care devices, while Erste Group slightly raised its 2027 EPS forecast to $6.06 from $6.05. Abbott Growth Trends
• Neutral Sentiment: Abbott began a roughly 1,000-patient real-world study of its TriClip heart-valve repair system. The study could strengthen adoption, but it also underscores rising competition from Edwards Lifesciences. Abbott Starts TriClip Study
• Neutral Sentiment: A personal-finance article included Abbott among dividend stocks suitable for long-term passive income, but it offered limited new company-specific information. Dividend Stocks for Passive Income
• Negative Sentiment: UBS lowered its price target from $135 to $125 while retaining a Buy rating, signaling somewhat less near-term upside despite continued confidence in Abbott’s fundamentals.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.